Literature DB >> 29077651

Exploring the Relationship Between Body Mass Index and Positive Symptom Severity in Persons at Clinical High Risk for Psychosis.

Fernando Caravaggio1, Gary Brucato, Lawrence S Kegeles, Eugénie Lehembre-Shiah, Leigh Y Arndt, Tiziano Colibazzi, Ragy Girgis.   

Abstract

Metabolic health and positive symptom severity has been investigated in schizophrenia, but not in clinical high risk (CHR) patients. We hypothesized that greater body mass index (BMI) in CHR patients would be related to less positive symptoms. We examined this relationship in CHR patients being treated with 1) no psychotropic medications (n = 58), 2) an antipsychotic (n = 14), or 3) an antidepressant without an antipsychotic (n = 10). We found no relationship between BMI and positive symptoms in unmedicated CHR patients, the majority of whom had a narrow BMI range between 20 and 30. However, in the smaller sample of CHR patients taking an antidepressant or antipsychotic, BMI was negatively correlated with positive symptoms. Although potentially underpowered, these preliminary findings provide initial steps in elucidating the relationships between metabolic health, neurochemistry, and symptom severity in CHR patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29077651      PMCID: PMC5678950          DOI: 10.1097/NMD.0000000000000736

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  12 in total

Review 1.  Consensus development conference on antipsychotic drugs and obesity and diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

2.  Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability.

Authors:  Tandy J Miller; Thomas H McGlashan; Joanna L Rosen; Kristen Cadenhead; Tyrone Cannon; Joseph Ventura; William McFarlane; Diana O Perkins; Godfrey D Pearlson; Scott W Woods
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

3.  Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia.

Authors:  Xiaoduo Fan; Emily Liu; Cynthia Pristach; Donald C Goff; David C Henderson
Journal:  Schizophr Res       Date:  2006-06-05       Impact factor: 4.939

Review 4.  Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.

Authors:  R S McIntyre; S M McCann; S H Kennedy
Journal:  Can J Psychiatry       Date:  2001-04       Impact factor: 4.356

5.  Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia.

Authors:  Song Chen; Dong Broqueres-You; Guigang Yang; Zhiren Wang; Yanli Li; Ning Wang; Xiangyang Zhang; Fude Yang; Yunlong Tan
Journal:  Psychiatry Res       Date:  2013-10-07       Impact factor: 3.222

Review 6.  Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants.

Authors:  Hubertus Himmerich; Juliane Minkwitz; Kenneth C Kirkby
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2015       Impact factor: 2.895

Review 7.  Weight gain and antidepressants.

Authors:  M Fava
Journal:  J Clin Psychiatry       Date:  2000       Impact factor: 4.384

8.  Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia.

Authors:  Fernando Caravaggio; Margaret Hahn; Shinichiro Nakajima; Philip Gerretsen; Gary Remington; Ariel Graff-Guerrero
Journal:  Med Hypotheses       Date:  2015-06-24       Impact factor: 1.538

9.  Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans.

Authors:  Fernando Caravaggio; Carol Borlido; Margaret Hahn; Zhe Feng; Gagan Fervaha; Philip Gerretsen; Shinichiro Nakajima; Eric Plitman; Jun Ku Chung; Yusuke Iwata; Alan Wilson; Gary Remington; Ariel Graff-Guerrero
Journal:  Int J Neuropsychopharmacol       Date:  2015-02-25       Impact factor: 5.176

10.  Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.

Authors:  Karen L Teff; Michael R Rickels; Joanna Grudziak; Carissa Fuller; Huong-Lan Nguyen; Karl Rickels
Journal:  Diabetes       Date:  2013-07-08       Impact factor: 9.461

View more
  3 in total

1.  Neutrophil Count Is Associated With Reduced Gray Matter and Enlarged Ventricles in First-Episode Psychosis.

Authors:  Christian Núñez; Christian Stephan-Otto; Judith Usall; Miquel Bioque; Antonio Lobo; Ana González-Pinto; Laura Pina-Camacho; Eduard Vieta; Josefina Castro-Fornieles; Roberto Rodriguez-Jimenez; Anna Butjosa; Joost Janssen; Bibiana Cabrera; Mara Parellada; Miquel Bernardo
Journal:  Schizophr Bull       Date:  2019-06-18       Impact factor: 9.306

2.  Body composition in Japanese patients with psychiatric disorders: A cross-sectional study.

Authors:  Taro Kishi; Makoto Okuya; Kenji Sakuma; Yohei Otaka; Eiichi Saitoh; Nakao Iwata
Journal:  Neuropsychopharmacol Rep       Date:  2021-01-28

3.  Dissecting clinical heterogeneity of bipolar disorder using multiple polygenic risk scores.

Authors:  Brandon J Coombes; Matej Markota; J John Mann; Colin Colby; Eli Stahl; Ardesheer Talati; Jyotishman Pathak; Myrna M Weissman; Susan L McElroy; Mark A Frye; Joanna M Biernacka
Journal:  Transl Psychiatry       Date:  2020-09-18       Impact factor: 6.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.